Chili peppers, nerve regeneration, and clinical trial design
Authors:
- 17 April 2007
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 68 (16) , 1247-1248
Abstract
One challenge for testing therapeutic approaches is the limited ability of currently available primary outcome measures such as clinical impairment scales and nerve conduction studies to document functional changes in small caliber sensory nerve fibers that are involved early in SN.4 A consequence is that subjects with relatively advanced SN are the focus of clinical trials. Furthermore, as the common forms of SN progress slowly, conventional outcome measures require lengthy studies (on the order of years) to demonstrate efficacy for slowing of progression.5Keywords
This publication has 11 references indexed in Scilit:
- Impaired reinnervation in HIV infection following experimental denervationNeurology, 2007
- Collateral sprouting of human epidermal nerve fibers following intracutaneous axotomyJournal of the Peripheral Nervous System, 2006
- Factors influencing nerve regeneration in a trial of timcodar dimesylateNeurology, 2006
- Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedsideBrain, 2005
- Quality of life and disability assessment in neuropathy: a multicentre studyJournal of the Peripheral Nervous System, 2005
- The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathyBrain, 2004
- Epidermal reinnervation after intracutaneous axotomy in manJournal of Comparative Neurology, 2003
- Incidence of and risk factors for HIV-associated distal sensory polyneuropathyNeurology, 2002
- Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory NeuropathyDiabetes Care, 2001
- Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic PolyneuropathyJAMA, 2000